Vertex Shrugs Off Q1 Miss With ‘Strong’ Journavx Launch, Encouraging Pipeline Position

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big PBMs to cover the non-opioid pain drug.

Scroll to Top